Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

20. Mai 2020 06:00 ET | Quelle: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing

Proceeds to support the clinical development of Atea’s oral, direct acting antiviral medicine for COVID-19, in addition to advancing its diverse pipeline of treatments for viral...
09. November 2018 08:01 ET | Quelle: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Present Positive Clinical Data with At-527 for the Treatment of Chronic Hepatitis C in Patients with Cirrhosis at The Liver Meeting ® 2018

AT-527 is a novel pan-genotypic purine nucleotide prodrug NS5B polymerase inhibitor AT-527 shows profound and equivalent pan-genotypic antiviral activity in cirrhotic and non-cirrhotic (NC) hepatitis...
12. April 2018 01:00 ET | Quelle: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Reports Positive Proof of Concept Clinical Data With AT-527 for the Treatment of Chronic Hepatitis C

AT-527 is a novel pan-genotypic purine nucleotide prodrug NS5B polymerase inhibitor which has been safe and well tolerated in this ongoing multiple part trial AT-527 exhibits potent antiviral activity...